HighGravityDataCurrent guidance
57 items
FMC Corporation
Guidance from FMC Corporation’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 29, 2026
Data checked
Jul 29, 2026
What changed in the Jul 29, 2026 release
Each item compared with the same item in the previous release (Apr 29, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Growth at midpoint vs. 2025 (Revenue Excl. India) | for FY2026 | — | “(7)%” | Filing ↗ |
| New | Growth at midpoint vs. 2025 (Revenue Excl. India) | for Q3 FY2026 | — | “(9)%” | Filing ↗ |
| New | Growth at midpoint vs. 2025 (Revenue Excl. India) | for Q4 FY2026 | — | “4%” | Filing ↗ |
| New | Revenue | for FY2026 | — | “$3.50 billion to $3.70 billion” | Filing ↗ |
| New | Revenue Excl. India | for FY2026 | — | “$3.50 billion to $3.70 billion” | Filing ↗ |
| New | Revenue Excl. India | for Q3 FY2026 | — | “$840 million to $900 million” | Filing ↗ |
| New | Revenue Excl. India | for Q4 FY2026 | — | “$1.06 billion to $1.20 billion” | Filing ↗ |
| New | Revenue excluding India | for Q3 FY2026 | — | “expected to be in the range of $840 million to $900 million” | Filing ↗ |
| New | Revenue excluding India | for Q4 FY2026 | — | “expected to be in the range of $1.06 billion to $1.20 billion” | Filing ↗ |
| New | Revenue excluding India (full-year) | for FY2026 | — | “a range of $3.50 billion to $3.70 billion” | Filing ↗ |
| New | Adjusted earnings per diluted share | for Q3 FY2026 | — | “$0.05 to $0.13” | Filing ↗ |
| New | Adjusted earnings per diluted share | for Q4 FY2026 | — | “$1.09 to $1.33” | Filing ↗ |
| New | Adjusted earnings per diluted share | for Q3 FY2026 | — | “in the range of $0.05 to $0.13” | Filing ↗ |
| New | Adjusted earnings per diluted share | for Q4 FY2026 | — | “in the range of $1.09 to $1.33” | Filing ↗ |
| New | Adjusted earnings per diluted share (full-year) | for FY2026 | — | “a range of $1.19 to $1.49” | Filing ↗ |
| New | Adjusted EBITDA | for Q3 FY2026 | — | “$120 million to $140 million” | Filing ↗ |
| New | Adjusted EBITDA | for Q4 FY2026 | — | “$275 million to $315 million” | Filing ↗ |
| New | Adjusted EBITDA | for Q3 FY2026 | — | “forecasted to be in the range of $120 million to $140 million” | Filing ↗ |
| New | Adjusted EBITDA | for Q4 FY2026 | — | “forecasted to be in the range of $275 million to $315 million” | Filing ↗ |
| Lowered | Adjusted EBITDA | for FY2026 | “$670 million to $730 million” | “$395 million to $455 million” | Filing ↗ |
| New | Adjusted EBITDA (full-year) | for FY2026 | — | “a range of $620 million to $680 million” | Filing ↗ |
| Lowered | Adjusted EPS | for FY2026 | “$1.63 to $1.89” | “$1.19 to $1.49” | Filing ↗ |
| New | Adjusted EPS | for Q3 FY2026 | — | “$0.05 to $0.13” | Filing ↗ |
| New | Adjusted EPS | for Q4 FY2026 | — | “$1.09 to $1.33” | Filing ↗ |
| New | Diluted shares assumed for EPS estimates | for Q3 FY2026 | — | “125.9 million diluted shares” | Filing ↗ |
| New | Debt-reduction proceeds target | for FY2026 | — | “approximately $1 billion of proceeds” | Filing ↗ |
| New | Free cash flow (full-year) | for FY2026 | — | “increased to a range of $75 million to $225 million” | Filing ↗ |
| New | Growth at midpoint vs. 2025 | for Q3 FY2026 | — | “(45)%” | Filing ↗ |
| New | Growth at midpoint vs. 2025 | for Q4 FY2026 | — | “4%” | Filing ↗ |
| New | India headwind (full-year outlook) | for FY2026 | — | “a 2 percent headwind” | Filing ↗ |
| New | Price (full-year outlook) | for FY2026 | — | “expected to be lower by mid-to-high single digits” | Filing ↗ |
| New | Volume | for Q3 FY2026 | — | “expected to be lower” | Filing ↗ |
| New | Volume | for Q4 FY2026 | — | “expected to show healthy growth” | Filing ↗ |
| New | Volume excluding India (full-year outlook) | for FY2026 | — | “expected to be in line with prior year” | Filing ↗ |
Show 15 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Revenue | for FY2026 | “$3.60 billion to $3.80 billion” | — | Filing ↗ |
| Not restated | Revenue (excl. India) | for FY2026 | “$3.60 billion to $3.80 billion” | — | Filing ↗ |
| Not restated | Revenue Excl. India | for H2 FY2026 | “$1.99 billion to $2.14 billion” | — | Filing ↗ |
| Not restated | Revenue excluding India | for FY2026 | “$3.60 billion to $3.80 billion” | — | Filing ↗ |
| Not restated | Adjusted EBITDA | for H2 FY2026 | “$468 million to $508 million” | — | Filing ↗ |
| Not restated | Adjusted EPS Growth at midpoint vs. 2025 | for FY2026 | “(102)%” | — | Filing ↗ |
| Not restated | Adjusted EPS^ | for H2 FY2026 | “$1.70 to $1.86” | — | Filing ↗ |
| Not restated | EPS (Adjusted earnings per diluted share) | for FY2026 | “$1.63 to $1.89” | — | Filing ↗ |
| Not restated | Second-half Adjusted EBITDA | for H2 FY2026 | “decrease 6 percent” | — | Filing ↗ |
| Not restated | Debt paydown | for FY2026 | “$1 billion” | — | Filing ↗ |
| Not restated | Debt reduction | for FY2026 | “approximately $1 billion” | — | Filing ↗ |
| Not restated | Free cash flow | for FY2026 | “negative $65 million to $65 million dollars” | — | Filing ↗ |
| Not restated | Price | for FY2026 | “lower by mid-single digits” | — | Filing ↗ |
| Not restated | Second-half sales | for H2 FY2026 | “increase of 1 percent” | — | Filing ↗ |
| Not restated | Volume (excluding India) | for FY2026 | “up modestly” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Growth at midpoint vs. 2025 (Revenue Excl. India) | “(7)%” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025 (Revenue Excl. India) | “(9)%” | for Q3 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025 (Revenue Excl. India) | “4%” | for Q4 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue | “$3.50 billion to $3.70 billion” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue | “$3.60 billion to $3.80 billion” | for FY2026 | GAAP-tied | Feb 4, 2026 | 1 | Filing ↗ |
| Revenue (excl. India) | “$3.60 billion to $3.80 billion” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Revenue Excl. India | “$3.50 billion to $3.70 billion” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue Excl. India | “$840 million to $900 million” | for Q3 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue Excl. India | “$1.06 billion to $1.20 billion” | for Q4 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue Excl. India | “$1.99 billion to $2.14 billion” | for H2 FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Revenue Excl. India Growth at midpoint vs. 2025 | “(11)%” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Revenue excluding India | “expected to be in the range of $840 million to $900 million” | for Q3 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue excluding India | “expected to be in the range of $1.06 billion to $1.20 billion” | for Q4 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Revenue excluding India | “$3.60 billion to $3.80 billion” | for FY2026 | GAAP-tied | Feb 4, 2026 | 1 | Filing ↗ |
| Revenue excluding India (full-year) | “a range of $3.50 billion to $3.70 billion” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted earnings per diluted share | “$0.05 to $0.13” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted earnings per diluted share | “$1.09 to $1.33” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted earnings per diluted share | “in the range of $0.05 to $0.13” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted earnings per diluted share | “in the range of $1.09 to $1.33” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted earnings per diluted share (full-year) | “a range of $1.19 to $1.49” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$120 million to $140 million” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$275 million to $315 million” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “forecasted to be in the range of $120 million to $140 million” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “forecasted to be in the range of $275 million to $315 million” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$395 million to $455 million” | for FY2026 | Company-defined | Feb 4, 2026 | 3 | Filing ↗ |
| Adjusted EBITDA | “$468 million to $508 million” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA (full-year) | “a range of $620 million to $680 million” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA Growth at midpoint vs. 2025 | “(17)%” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Adjusted EPS | “$1.19 to $1.49” | for FY2026 | Company-defined | Feb 4, 2026 | 2 | Filing ↗ |
| Adjusted EPS | “$0.05 to $0.13” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EPS | “$1.09 to $1.33” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Adjusted EPS Growth at midpoint vs. 2025 | “(102)%” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Adjusted EPS^ | “$1.70 to $1.86” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Diluted shares assumed for EPS estimates | “125.9 million diluted shares” | for Q3 FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| EPS (Adjusted earnings per diluted share) | “$1.63 to $1.89” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025 (Adjusted EPS) | “$(1.20)” | for FY2026 | Company-defined | Feb 4, 2026 | 1 | Filing ↗ |
| Second-half Adjusted EBITDA | “decrease 6 percent” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Second-half Adjusted EPS | “decline 15 percent” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Additional tariff charges | “approximately $20 million” | for FY2026 | Company-defined | Feb 4, 2026 | 1 | Filing ↗ |
| Debt paydown | “$1 billion” | for FY2026 | Company-defined | Feb 4, 2026 | 1 | Filing ↗ |
| Debt reduction | “approximately $1 billion” | for FY2026 | Company-defined | Feb 4, 2026 | 2 | Filing ↗ |
| Debt-reduction proceeds target | “approximately $1 billion of proceeds” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Free cash flow | “negative $65 million to $65 million dollars” | for FY2026 | Company-defined | Feb 4, 2026 | 2 | Filing ↗ |
| Free cash flow (full-year) | “increased to a range of $75 million to $225 million” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025 | “(45)%” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025 | “4%” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Growth at midpoint vs. 2025* | “(15)%” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| India headwind | “2 percent headwind” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| India headwind (full-year outlook) | “a 2 percent headwind” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Price | “lower by mid-single digits” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Price (full-year outlook) | “expected to be lower by mid-to-high single digits” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Sales of new active ingredients | “between $300 million and $400 million” | for FY2026 | Company-defined | Feb 4, 2026 | 2 | Filing ↗ |
| Second-half sales | “increase of 1 percent” | for H2 FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Volume | “expected to be lower” | for Q3 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Volume | “expected to show healthy growth” | for Q4 FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Volume (excluding India) | “up modestly” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Volume excluding India (full-year outlook) | “expected to be in line with prior year” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Quarterly dividend | “$0.08 per share” | — | Declared action | Oct 29, 2025 | 1 | Filing ↗ |
How one item moved
Adjusted EBITDA, for FY2026 — every statement across the year, each linked to its filing.
How your Specialty chemicals sector group guides
12 companies in Specialty chemicals. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| RPM International | Oct 6, 2026 | 5 changes |
| Albemarle | Aug 5, 2026 | 24 changes |
| DuPont | Aug 4, 2026 | 11 changes |
| Cabot Corporation | Aug 3, 2026 | 4 changes |
| Eastman Chemical | Jul 30, 2026 | 9 changes |
| Huntsman | Jul 30, 2026 | 1 change |
| FMC Corporation | Jul 29, 2026 | 34 changes |
| Ashland | Jul 28, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|
| Growth at midpoint vs. 2025 (Revenue Excl. India) | 8 statements | 8 statements | — | — |
| Revenue | 5 statements | 11 statements | 2 statements | — |
| Revenue - First-Half Outlook | — | 2 statements | — | — |
| Revenue Excl. India | 6 statements | 1 statement | — | — |
| Revenue Excl. India Growth at midpoint vs. 2025 | 2 statements | — | — | — |
The full record for FMC Corporation and its Specialty chemicals peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 29, 2026 | FY2026 Q2 | 0000037785-26-000139 | 35 | Open filing ↗ |
| Apr 29, 2026 | FY2026 Q1 | 0000037785-26-000083 | 35 | Open filing ↗ |
| Feb 4, 2026 | FY2025 Q4 | 0000037785-26-000036 | 17 | Open filing ↗ |
| Oct 29, 2025 | FY2025 Q3 | 0000037785-25-000123 | 21 | Open filing ↗ |
| Jul 30, 2025 | FY2025 Q2 | 0000037785-25-000078 | 20 | Open filing ↗ |
| Apr 30, 2025 | FY2025 Q1 | 0000037785-25-000054 | 40 | Open filing ↗ |
| Feb 4, 2025 | FY2024 Q4 | 0000037785-25-000012 | 19 | Open filing ↗ |
| Oct 29, 2024 | FY2024 Q3 | 0000037785-24-000112 | 18 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error